GoodRx Holdings, Inc. (NASDAQ: GDRX) saw its stock price surge 5.98% in after-hours trading on Wednesday following the release of its first-quarter 2025 financial results. The leading platform for medication savings in the U.S. reported in-line revenue and beat expectations on adjusted EBITDA, while maintaining its full-year revenue guidance and raising its adjusted EBITDA outlook.
For the first quarter of 2025, GoodRx reported revenue of $203 million, aligning with the IBES estimate of $202.2 million. The company's adjusted EBITDA came in at $69.8 million, surpassing the IBES estimate of $67 million. Notably, the adjusted EBITDA margin improved to 34.4%, demonstrating the company's ability to enhance profitability.
Investors were particularly encouraged by GoodRx's outlook for the remainder of 2025. The company maintained its full-year revenue guidance range of $810 to $840 million, representing a 2% to 6% growth compared to 2024. Additionally, GoodRx raised its adjusted EBITDA expectations for the full year to between $273 and $287 million, indicating a 5% to 10% growth over 2024. The company also provided a positive outlook for the second quarter, expecting revenue to increase sequentially from the first quarter's $203 million, with an adjusted EBITDA margin similar to Q1. This strong performance and optimistic forecast likely contributed to the stock's after-hours rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.